Chat with ILD AI
Hi, I am ILD AI.
ILD AI 11:47 AM
Back Evolving IPF Care: The Significance of Nerandomilast’s FDA Approval
October 2025
In this special crossover episode, host Amanda Mixon, PA-C, President of RhAPP, sits down with Corinne Young, FNP-C, founder and President of the Association of Pulmonary Advanced Practice Providers (APAPP), to discuss one of the most exciting developments in interstitial lung disease: the FDA approval of nerandomilast for idiopathic pulmonary fibrosis (IPF). This breakthrough marks the first new IPF therapy in more than a decade and introduces a novel PDE4B mechanism of action designed to reduce fibrosis and improve lung function. Together, Amanda and Corrine unpack the clinical data behind nerandomilast, key findings from the FIBRONEER-IPF trial, and how its safety profile—particularly reduced GI side effects—may reshape treatment pathways and patient quality of life. The conversation also highlights the overlap between rheumatology and pulmonology in managing fibrotic lung diseases and the importance of interdisciplinary collaboration as additional indications for progressive pulmonary fibrosis (PPF) are anticipated.
#Rheumatology #Pulmonology #InterstitialLungDisease #IPF #Nerandomilast #Fibrosis #AdvancedPracticeProviders #APPs #FDAApproval #ClinicalUpdates
Related Podcasts
The Role of APPs in Advanced ILD/PH ILD
August 2026
18:12 m
In this ILD Community Network podcast episode, host Kelsey Cramer is joined by Jenny Williams, for a practical discussion on the role of advanced practice providers in advanced interstitial lung disease and pulmonary hypertension associated with interstitial lung disease, also known as PH-ILD. Together, they explore how APPs can recognize high-risk signs of disease progression, including worsening shortness of breath, declining exercise tolerance, increasing oxygen needs, changes in pulmonary function tests, reduced six-minute walk distance, and signs of right heart strain or pulmonary hypertension. This episode also highlights when clinicians should consider referral to ILD specialty centers, pulmonary hypertension clinics, lung transplant evaluation, pulmonary rehab, anti-fibrotic therapy, inhaled therapy for PH-ILD, and palliative care support. Listeners will gain practical insights into identifying advanced ILD, understanding PH-ILD risk factors, recognizing transplant referral triggers, coordinating multidisciplinary care, and ensuring patients receive timely access to specialized treatment and advanced therapies.
Practical Considerations for Screening for PH in ILD Clinics
July 2025
17:17 m
In this insightful Podcast, expert advanced practice providers, Corinne Young & Jessica Glennie share practical strategies for identifying and screening for pulmonary hypertension (PH) in patients with interstitial lung disease (ILD). They discuss how to recognize subtle red flags—such as declining DLCO, changes in walk test performance, and discrepancies in pulmonary function test results—that may indicate the presence of PH. The conversation also covers when to order echocardiograms, when to refer for right heart catheterization, and how to distinguish ILD progression from the development of PH. With a focus on multidisciplinary collaboration and real-world clinical workflows, this episode offers valuable, actionable guidance for APPs, pulmonologists, and care teams managing ILD populations.
Immunology of the Lung Podcast
July 2025
11:40 m
Tune in from the Annual APAPP National Conference for a dynamic episode of the APAPP Podcast featuring Corinne Young, FNP-C, Amanda Michaud, PA-C, and Brian Bizik, PA-C—three expert APPs leading engaging sessions on lung immunology, rare immune deficiencies, and COPD updates. Amanda breaks down the “Immunology of the Lung 101” and her “Finding the Zebras” series, where she highlights key red flags for primary immune deficiencies, sharing real patient cases and diagnostic tips to help clinicians recognize and manage these commonly missed conditions. Brian shares practical takeaways from the latest GOLD COPD guidelines, including how biomarkers like eosinophil counts can guide personalized inhaled corticosteroid decisions. Whether you're managing patients with asthma, COPD, or unexplained recurrent infections, this episode delivers clinical pearls you can apply in your practice right away. Discover why this APP-led meeting stands out as a must-attend event for pulmonary and immunology providers. Be sure to like, subscribe, and follow us for more expert-driven conversations.
Understanding MAC with Jennifer Faber- Gerling
December 2024
30:30 m
In this episode, Corinne Young interviews Jennifer Faber- Gerling about mycobacterium avian complex (MAC). They discuss the bacterium itself, the rise in cases, screening and diagnosis, treatment and side effects, reinfection versus reactivation, and symptom management. Jennifer emphasized the importance of close surveillance, collaboration with a multidisciplinary team, and individualized care for patients with MAC.
Podcast: Recognizing PH-ILD Earlier: Missed Signals, Delayed Diagnosis, and How to Close the Gap
February 2026
31:14 m
Pulmonary hypertension associated with interstitial lung disease (PH-ILD) is one of the most impactful—and often underrecognized—complications in patients with established ILD, frequently presenting with symptoms that mimic ILD progression. In this ILD Community Network podcast episode, Amanda Mixon is joined by Corinne Young to break down why PH-ILD is missed, what red flags clinicians should watch for, and when to escalate evaluation beyond “worsening ILD.” The discussion highlights practical screening cues such as disproportionate DLCO decline, stable imaging with worsening dyspnea, enlarged pulmonary arteries on high-resolution CT, and revealing echocardiogram findings including RV/RA enlargement, TAPSE, and tricuspid regurgitation—along with the limitations of echo estimates and the role of right heart catheterization for confirmation. Tune in for real-world strategies to improve earlier recognition, reduce diagnostic delays, and strengthen multidisciplinary collaboration between rheumatology, pulmonology, and primary care to improve outcomes for patients living with ILD and PH-ILD. #InterstitialLungDisease #PulmonaryHypertension #PHILD #Rheumatology #Pulmonology #AdvancedPracticeProviders #MedicalEducation #ILDCommunityNetwork #APAPP #RhAPP
ILD & PH-ILD at the Rheum–Pulm Crossroads
November 2025
22:52 m
Join host Amanda Mixon, President of RhAPP, for a special episode recorded live at the 6th Annual RhAPP Conference. In this conversation, Amanda is joined by Jessica Glennie, CNP, from the Cleveland Clinic, to explore the complex intersection of rheumatology and pulmonology, focusing on Interstitial Lung Disease (ILD) and Pulmonary Hypertension in ILD (PH-ILD). Together, they unpack how early recognition, multidisciplinary collaboration, and evidence-based management can improve outcomes for patients with connective tissue disease–related pulmonary complications. Tune in for expert insights, practical diagnostic tips, and highlights from one of the most engaging sessions of the RhAPP National Conference.
Deep Dive Into ILD Therapeutics
December 2024
37:59 m
Check out this podcast recording from the 2024 APAPP Conference in Vegas!
Advancing ILD & PH-ILD Care
July 2025
21:35 m
Join Jessica Glennie, APRN, and Lori Reed, FNP, from the 2025 APAPP National Conference as they discuss key insights in diagnosing and managing interstitial lung disease (ILD) and pulmonary hypertension (PH). From interpreting PFTs and recognizing red flags to exploring current and emerging therapies like inhaled treprostinil and neuredomast, this episode offers practical strategies for improving patient care. Tune in for expert tips and updates every pulmonary provider should know.
Idiopathic Shortness of Breath Part 1 Using CPET
December 2024
26:37 m
National Jewish Health’s NP, Cori Fratelli, shares with us how she and her colleagues utilize CPET and other testing in patients with unexplained shortness of breath.
Rheumatology in the Lungs
July 2025
24:47 m
How can Advanced Practice Providers (APPs) in rheumatology and pulmonology collaborate more effectively to manage interstitial lung disease (ILD) and connective tissue diseases (CTDs)? In this engaging episode of the APAPP Broadcast, recorded live at the Second Annual National APAPP Conference in Nashville, experts Jessica Glennie, PA-C (Cleveland Clinic), Amanda Mixon, PA-C (Colorado), and Cori Fratelli, NP (National Jewish Health) explore clinical overlaps between autoimmune rheumatic diseases and lung involvement, such as ILD in rheumatoid arthritis, systemic sclerosis (scleroderma), Sjögren’s syndrome, and myositis. The panel shares clinical pearls on: -How to recognize signs of CTDs in pulmonary patients -The importance of labs and imaging in early diagnosis -What rheumatology APPs should ask about pulmonary symptoms -The power of cross-specialty collaboration -Real-world case insights, including navigating bird-related hypersensitivity pneumonitis